Physician profile
Avinash Linganna
NPI 1437362951
$609.57
in general payments reported to CMS, 2019-2025
12 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $8.65 · 2023: $340 · 2024: $122 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $175.27 | 2023-2025 | |
| Novo Nordisk INC | $112.75 | 2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $76.85 | 2023-2025 | Farxiga, Andexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.09 | 2022-2025 | Lifevest |
| Heartflow, INC. | $50.11 | 2023 | Ffrct |
| Abiomed | $41.89 | 2024 | Impella |
| Scpharmaceuticals INC. | $18.57 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2023 | Eliquis |
| Amgen INC. | $13.25 | 2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $13.03 | 2023 | |
| Cvrx, INC. | $7.45 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Linganna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.